drugset / Trial / NCT00332930
ITV Extension Study
Phase 1/2
Completed
35 enrolled
Kirby Institute
The University of New South Wales · collabVirax Pty. Ltd, · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this phase I/II therapeutic human immunodeficiency virus (HIV) vaccine candidate study is to provide proof of concept for a HIV antigen delivery system in terms of safety, virological effects and selected immune responses in HIV infected individuals after cessation of antiretroviral combination therapy (ART).
Timeline
- Start
- 2002-09
- Primary completion
- —
- Completion
- 2003-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HIV gag-pol antigens | Unknown | — | Intramuscular |
| Subject | interferon gamma | Protein / enzyme biologic | — | Intramuscular |
| Subject | recombinant fowlpoxvirus | Vaccine | — | Intramuscular |